GSA Capital Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,990
| Closed | -$989K | – | 1719 |
|
|
2026
Q1 | $989K | Buy |
+2,990
| New | +$1.02M | 0.06% | 500 |
|
|
2025
Q4 | – | Sell |
-476
| Closed | -$217K | – | 1639 |
|
|
2025
Q3 | $217K | Buy |
+476
| New | +$194K | 0.02% | 1387 |
|
|
2025
Q1 | – | Sell |
-4,360
| Closed | -$1.03M | – | 1611 |
|
|
2024
Q4 | $1.03M | Buy |
4,360
+1,500
| +52% | +$394K | 0.08% | 391 |
|
|
2024
Q3 | $787K | Buy |
2,860
+1,018
| +55% | +$265K | 0.06% | 615 |
|
|
2024
Q2 | $448K | Buy |
+1,842
| New | +$291K | 0.03% | 1039 |
|
|
2023
Q2 | – | Sell |
-1,042
| Closed | -$209K | – | 1482 |
|
|
2023
Q1 | $209K | Buy |
+1,042
| New | +$219K | 0.02% | 1237 |
|
|
2022
Q4 | – | Sell |
-1,239
| Closed | -$248K | – | 1430 |
|
|
2022
Q3 | $248K | Buy |
+1,239
| New | +$236K | 0.03% | 1058 |
|
|
2022
Q2 | – | Sell |
-2,554
| Closed | -$417K | – | 1365 |
|
|
2022
Q1 | $417K | Buy |
+2,554
| New | +$389K | 0.06% | 661 |
|
|
2021
Q3 | – | Sell |
-2,732
| Closed | -$463K | – | 1388 |
|
|
2021
Q2 | $463K | Buy |
2,732
+1,122
| +70% | +$164K | 0.05% | 680 |
|
|
2021
Q1 | $227K | Buy |
+1,610
| New | +$242K | 0.04% | 819 |
|
|
2018
Q2 | – | Sell |
-2,573
| Closed | -$306K | – | 1648 |
|
|
2018
Q1 | $306K | Buy |
+2,573
| New | +$332K | 0.02% | 1301 |
|
|
2017
Q3 | – | Sell |
-7,206
| Closed | -$575K | – | 1577 |
|
|
2017
Q2 | $575K | Buy |
+7,206
| New | +$461K | 0.04% | 932 |
|
|
2016
Q4 | – | Sell |
-3,959
| Closed | -$268K | – | 1724 |
|
|
2016
Q3 | $268K | Sell |
3,959
-2,864
| -42% | -$202K | 0.01% | 1444 |
|
|
2016
Q2 | $379K | Buy |
6,823
+3,099
| +83% | +$195K | 0.02% | 1250 |
|
|
2016
Q1 | $234K | Sell |
3,724
-701
| -16% | -$46.6K | 0.01% | 1426 |
|
|
2015
Q4 | $417K | Sell |
4,425
-42,499
| -91% | -$3.94M | 0.02% | 1269 |
|
|
2015
Q3 | $3.77M | Buy |
46,924
+2,256
| +5% | +$251K | 0.19% | 71 |
|
|
2015
Q2 | $5.35M | Buy |
44,668
+39,770
| +812% | +$4.75M | 0.21% | 46 |
|
|
2015
Q1 | $511K | Sell |
4,898
-7,185
| -59% | -$728K | 0.02% | 1377 |
|
|
2014
Q4 | $1.17M | Buy |
+12,083
| New | +$1.12M | 0.08% | 375 |
|
|
2014
Q3 | – | Sell |
-7,839
| Closed | -$495K | – | 1697 |
|
|
2014
Q2 | $495K | Sell |
7,839
-12,261
| -61% | -$729K | 0.02% | 1148 |
|
|
2014
Q1 | $1.35M | Buy |
+20,100
| New | +$1.56M | 0.1% | 218 |
|
Other funds holding ALNY
GSA Capital Partners's ALNY Position: Q2 2026 in Review
GSA Capital Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 2,990 shares — an estimated $989K sold.
GSA Capital Partners first reported a position in ALNY in Q1 2014 and held it in 22 quarters. The position peaked at $5.35M in Q2 2015. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- GSA Capital Partners reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- GSA Capital Partners sold 2,990 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $989K.
- GSA Capital Partners first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 22 quarters.
- GSA Capital Partners's Alnylam Pharmaceuticals position peaked at $5.35M in Q2 2015.
- 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.